Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099895 | 0.78 | ALDH1A1 (0.45) | ALDH1A1KMT2AMEN1KEAP1NPSR1 | |
| SCHEMBL608745 | 0.77 | CAPN1 (0.69) | CAPN1ALDH1A1KMT2AKEAP1 | |
| SCHEMBL20809659 | 0.76 | CAPN1 (0.49) | CAPN1ALDH1A1KMT2ATRPM8 | |
| SCHEMBL27844841 | 0.76 | CAPN1 (1.00) | CAPN1ALDH1A1KMT2ATRPM8KEAP1 | |
| SCHEMBL9775265 | 0.74 | CAPN1 (0.59) | CAPN1ALDH1A1KMT2ATRPM8 | |
| SCHEMBL9775301 | 0.74 | CAPN1 (0.59) | CAPN1ALDH1A1KMT2ATRPM8 | |
| SCHEMBL7390667 | 0.74 | CAPN1 (0.50) | CAPN1ALDH1A1KMT2AMEN1 | |
| SCHEMBL105766 | 0.73 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1KEAP1 | |
| SCHEMBL19658332 | 0.72 | ALDH1A1 (0.59) | ALDH1A1KMT2AMEN1KEAP1NPSR1 | |
| SCHEMBL2625210 | 0.72 | FFAR1 (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075390-A1 | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6852711-B2 | Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | disclosed |
| US-6528510-B1 | Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| EP-1112269-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015634-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106606-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | CAPN1 2030/4885ALDH1A1 1219/4885KMT2A 2939/4885 |
| US-20050075390-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | CAPN1 2037/4885ALDH1A1 1309/4885KMT2A 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.